Novartis stock holds firm as Pluvicto grows 43% in Q2

Novartis stock is framed by Q2 2026 sales of $14.4 billion, core EPS of $2.41 and Pluvicto growth of 43% in constant currencies.

Novartis AG (CH0012005267) is anchored by second-quarter 2026 sales of $14.4 billion, core EPS of $2.41 and a 43% constant-currency jump in Pluvicto, all of which shape the stock's August 24, 2026 setup.

Those figures come from a recent market report that also says Novartis reaffirmed 2026 guidance for low single-digit net sales growth and a low single-digit decline in core operating income. The same report puts first-half 2026 sales at $27.5 billion, with core operating income at $10.8 billion and net income at $6.4 billion.

Q2 sales and guidance

The quarter was driven by growth brands including Kisqali, Kesimpta, Scemblix and Pluvicto, with Pluvicto at $651 million in Q2 2026 and Scemblix at $562 million. Core EPS of $2.41 also beat the cited analyst estimate of $2.13, a gap of 13.15%.

For investors, the key comparison is simple: first-half 2026 net sales were $27.5 billion while core operating income reached $10.8 billion, leaving the margin path dependent on how the second half develops. The same report says net income for the first half fell 17% in constant currencies.

Pipeline and position

Novartis's radioligand push matters because Pluvicto still appears to be scaling, and management said it wants to move beyond Pluvicto and Lutathera into additional cancer types. That keeps pipeline execution and new label opportunities in the frame alongside the 2026 guidance.

The company's market value was put at $294 billion in a recent article on August 23, 2026, which places Novartis among the larger global health-care names even after the Q2 reset.

Representative product

Pluvicto is Novartis's radioligand therapy for advanced prostate cancer, and the Q2 2026 update showed $651 million in sales, up 43% in constant currencies. That makes the product a key indicator for how far the company can extend its oncology growth story.

Stock level

Novartis stock trades on the NYSE as NVS. The market value cited above was $294 billion on August 23, 2026.

Fact box

Company: Novartis AG
ISIN: CH0012005267
Ticker: NVS
Exchange: NYSE
Market cap: $294 billion (August 23, 2026)
Sector / Industry: Health Care / Pharmaceuticals